WO2003106667A2
(fr)
*
|
2002-06-12 |
2003-12-24 |
Bayer Healthcare Ag |
Regulation d'une serine protease de type subtilase humaine
|
EP1471152A1
(fr)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2444494B1
(fr)
|
2006-10-09 |
2016-09-28 |
Roche Innovation Center Copenhagen A/S |
Composés antagonistes de l'arn pour la modulation de pcsk9
|
JP5588175B2
(ja)
|
2006-11-07 |
2014-09-10 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Pcsk9のアンタゴニスト
|
CA2680832A1
(fr)
|
2007-03-27 |
2008-10-02 |
Merck & Co., Inc. |
Procede de detection de pcsk9 secretee, autogeneree
|
CN101679527A
(zh)
*
|
2007-04-13 |
2010-03-24 |
诺瓦提斯公司 |
用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
AR070316A1
(es)
*
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
TWI445716B
(zh)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9拮抗劑類
|
WO2010068526A1
(fr)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Immunodosage de pcsk9
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
WO2011009697A1
(fr)
|
2009-07-21 |
2011-01-27 |
Santaris Pharma A/S |
Oligomères anti-sens ciblant pcsk9
|
AU2010313381A1
(en)
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX1 and AX189 PCSK9 antagonists and variants
|
CN102639150A
(zh)
|
2009-10-30 |
2012-08-15 |
默沙东公司 |
Ax213和ax132 pcsk9拮抗剂和变体
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
AR084938A1
(es)
|
2011-01-28 |
2013-07-10 |
Sanofi Sa |
Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
AU2012308797B2
(en)
|
2011-09-16 |
2017-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9)
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
BR112014031310A2
(pt)
|
2012-06-15 |
2017-07-25 |
Genentech Inc |
anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
|
US9540449B2
(en)
|
2012-08-13 |
2017-01-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-PCSK9 antibodies with pH-dependent binding characteristics
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
KR20160024906A
(ko)
|
2013-06-07 |
2016-03-07 |
사노피 바이오테크놀로지 |
Pcsk9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
|
EP3591054A1
(fr)
|
2013-06-27 |
2020-01-08 |
Roche Innovation Center Copenhagen A/S |
Oligomères et conjugués antisens ciblant pcsk9
|
EP3882273A1
(fr)
|
2013-11-12 |
2021-09-22 |
Sanofi Biotechnology |
Schémas posologiques pour une utilisation avec des inhibiteurs de pcsk9
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB2521355A
(en)
*
|
2013-12-17 |
2015-06-24 |
Kymab Ltd |
Human targets I
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
KR20170029613A
(ko)
|
2014-07-16 |
2017-03-15 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
EP3337828A1
(fr)
|
2015-08-18 |
2018-06-27 |
Regeneron Pharmaceuticals, Inc. |
Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
|
WO2018083248A1
(fr)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
|
AU2017382323B2
(en)
|
2016-12-23 |
2024-06-13 |
President And Fellows Of Harvard College |
Gene editing of PCSK9
|
WO2019041066A1
(fr)
*
|
2017-08-26 |
2019-03-07 |
深圳市博奥康生物科技有限公司 |
Construction d'un vecteur d'expression eucaryote fh3 et préparation d'une souche cellulaire à haute expression à l'aide de celui-ci
|
WO2021207711A2
(fr)
|
2020-04-09 |
2021-10-14 |
Verve Therapeutics, Inc. |
Arn guides modifiés chimiquement pour l'édition du génome avec cas9
|